SCHEMBL8242559

SCHEMBL8242559

COc1ncccc1C(=O)C(C)(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.45
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
NFE2L2 Q16236 4/20 0.43
SLC13A5 Q86YT5 1/20 0.42
RAB9A P51151 2/20 0.41
SLC22A12 Q96S37 1/20 0.41
LMNA P02545 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
HPGD P15428 1/20 0.40
NPC1 O15118 2/20 0.40
TSHR P16473 1/20 0.40
BRD4 O60885 1/20 0.39
BRPF1 P55201 1/20 0.39
PPARG P37231 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
NCOR2 Q9Y618 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17863855 0.83 NPC1 (0.57) GAAMAPTLMNASMN1; SMN2HPGD
SCHEMBL949562 0.82 TDP1 (0.50) TDP1GAAMAPTSLC13A5RAB9A
SCHEMBL22837050 0.81 NPC1 (0.42) TDP1GAARAB9ALMNAHPGD
SCHEMBL8427582 0.80 TDP1 (0.49) TDP1GAAMAPTSLC13A5RAB9A
SCHEMBL31081770 0.80 TDP1 (0.49) TDP1GAAMAPTSLC13A5RAB9A
SCHEMBL18201 0.80 TDP1 (0.57) TDP1GAAMAPTSLC13A5RAB9A
SCHEMBL30592857 0.80 TDP1 (0.57) TDP1GAAMAPTSLC13A5RAB9A
SCHEMBL19599247 0.80 HCRTR2 (0.52) LMNASMN1; SMN2NPC1
SCHEMBL6609846 0.79 TDP1 (0.47) TDP1GAAMAPTSLC13A5RAB9A
SCHEMBL5073283 0.79 TDP1 (0.47) TDP1GAAMAPTSLC13A5RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 US disclosed
US-20090111828-A1 L-ALANINE DERIVATIVES ASTRAZENECA AB 2009-04-30 US disclosed
WO-2007060409-A1 L-ALANINE DERIVATIVES ASTRAZENECA AB (SE) 2007-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111828-A1 L-ALANINE DERIVATIVES ITGA2B, ITGB1, ITGB5 TDP1 3330/4885GAA 1437/4885MAPT 3535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.